Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type < em > TP53 < /em >

CONCLUSION: ALRN-6924 was well tolerated and demonstrated anti-tumor activity.PMID:34301750 | DOI:10.1158/1078-0432.CCR-21-0715

Source: Clinical Cancer Research - July 24, 2021 Category: Cancer & Oncology Authors: Mansoor N Saleh Manish R Patel Todd M Bauer Sanjay Goel Gerald S Falchook Geoffrey I Shapiro Ki Y Chung Jeffrey R Infante Robert M Conry Guilherme Rabinowits David S Hong Judy S Wang Ulrich Steidl Gurudatta Naik Vincent Guerlavais Vojislav Vukovic D Allen Source Type: research